2018 - Fellow, National Academy of Inventors
2010 - Fellow of the American Society of Mechanical Engineers
Mauro Ferrari spends much of his time researching Nanotechnology, Nanomedicine, Nanoparticle, Drug delivery and Silicon. His work often combines Nanotechnology and Extramural studies. As part of the same scientific family, Mauro Ferrari usually focuses on Nanomedicine, concentrating on Nanocarriers and intersecting with Risk analysis.
His Nanoparticle research includes themes of Molecular targeting, Porous silicon, Endocytosis and Biodistribution. His studies deal with areas such as Cancer and Immunology as well as Drug delivery. His study in Silicon is interdisciplinary in nature, drawing from both Nanoporous, Kinetics and Mesoporous material.
The scientist’s investigation covers issues in Nanotechnology, Drug delivery, Nanoparticle, Cancer research and Cancer. Mauro Ferrari specializes in Nanotechnology, namely Nanomedicine. His Drug delivery study incorporates themes from Biomedical engineering and Pharmacology, Drug.
Nanoparticle is closely attributed to Porous silicon in his research. His Cancer research research integrates issues from Cancer cell, Breast cancer, Immunology and In vivo. Mauro Ferrari interconnects Doxorubicin and Pathology in the investigation of issues within In vivo.
His primary areas of study are Cancer research, Drug delivery, Cancer, In vivo and Nanomedicine. His Cancer research research is multidisciplinary, incorporating elements of Chemotherapy, Doxorubicin, Cancer cell, Antigen and Immunotherapy. His Drug delivery study is focused on Nanotechnology in general.
The Nanotechnology study combines topics in areas such as Vascular compartment, Active ingredient, Multicomponent systems and Microparticle. The study incorporates disciplines such as Cell and Oncology in addition to Cancer. His Nanomedicine study combines topics from a wide range of disciplines, such as Nanocarriers, Macrophage and Biodistribution.
Mauro Ferrari focuses on Drug delivery, Cancer, Cancer research, Nanomedicine and Immunology. His Drug delivery study contributes to a more complete understanding of Nanotechnology. The various areas that Mauro Ferrari examines in his Cancer study include Survival rate, Efficacy, Tolerability and Oncology.
His research in Cancer research intersects with topics in Autophagy, Cancer cell, Doxorubicin, Molecular biology and In vivo. He has researched Nanomedicine in several fields, including Internal medicine, Engineering ethics and Biodistribution. His studies deal with areas such as Foreign Bodies, Computational biology and Liposome as well as Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cancer nanotechnology: opportunities and challenges.
Mauro Ferrari.
Nature Reviews Cancer (2005)
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Elvin Blanco;Haifa Shen;Haifa Shen;Mauro Ferrari;Mauro Ferrari.
Nature Biotechnology (2015)
Nanomedicine--challenge and perspectives.
Kristina Riehemann;Stefan W. Schneider;Thomas A. Luger;Biana Godin.
Angewandte Chemie (2009)
Size and shape effects in the biodistribution of intravascularly injected particles.
P. Decuzzi;B. Godin;T. Tanaka;S. Y. Lee.
Journal of Controlled Release (2010)
Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications
Ennio Tasciotti;Xuewu Liu;Rohan Bhavane;Kevin Plant.
Nature Nanotechnology (2008)
Clinical proteomics: Written in blood
Lance A. Liotta;Mauro Ferrari;Emanuel Petricoin.
Nature (2003)
Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions
Alessandro Parodi;Nicoletta Quattrocchi;Nicoletta Quattrocchi;Anne L. van de Ven;Ciro Chiappini.
Nature Nanotechnology (2013)
Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?
Paolo Decuzzi;Renata Pasqualini;Wadih Arap;Mauro Ferrari;Mauro Ferrari.
Pharmaceutical Research (2009)
Nanotechnologies for biomolecular detection and medical diagnostics
Mark Ming Cheng Cheng;Giovanni Cuda;Yuri L. Bunimovich;Marco Gaspari.
Current Opinion in Chemical Biology (2006)
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
Xi Chen;Dimitrios Iliopoulos;Dimitrios Iliopoulos;Qing Zhang;Qianzi Tang;Qianzi Tang.
Nature (2014)
Italian Institute of Technology
University of California, San Francisco
Texas Tech University
University of Padua
The University of Texas MD Anderson Cancer Center
University of Washington
The University of Texas MD Anderson Cancer Center
Chinese Academy of Sciences
The University of Texas Health Science Center at Houston
The University of Texas MD Anderson Cancer Center
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: